Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response
Author: Ghaly, S.
Costello, S.
Beswick, L.
Pudipeddi, A.
Agarwal, A.
Sechi, A.
Antoniades, S.
Headon, B.
Connor, S.
Lawrance, I.
Sparrow, M.
Walsh, A.
Andrews, J.
Citation: Internal Medicine Journal, 2015; 45(2):170-177
Publisher: Wiley
Issue Date: 2015
ISSN: 1444-0903
Statement of
S. Ghaly, S. Costello, L. Beswick, A. Pudipeddi, A. Agarwal, A. Sechi, S. Antoniades, B. Headon, S. Connor, I. C. Lawrance, M. Sparrow, A. J. Walsh, and J. M. Andrews, on behalf of AIBDA
Abstract: Background: ‘Dose tailoring' of anti-tumour necrosis factor alpha (TNF-α) therapy in Crohn disease (CD), by dose escalation, or shortening of dosing intervals, has been suggested to regain clinical response following a flare in a proportion of patients. However, reported outcome data are sparse and none exists from Australia.Method: In an observational multicentre, retrospective study, the impact of anti-TNF-α dose tailoring on corticosteroid use, the need for surgery and physician perception of clinical efficacy was examined in a real-world setting at six Australian adult teaching hospitals. Demographics, disease characteristics, medications, indication for and duration of dose tailoring were documented. Results: Fifty-five CD patients were identified as requiring dose tailoring and secondary loss of response was the indication in 96%. Either adalimumab (64%) or infliximab (36%) was dose escalated for a median of 5 months (range 1-47), with a median of 20 months follow up (range 3-65). At 3 months, dose tailoring reduced the mean number of days on high-dose corticosteroids (45 vs 23, P = 0.01). Most (78%) patients remained resection free, and 73% of physicians reported good clinical efficacy of dose tailoring. Of those who de-escalated therapy due to induction of remission, long-term (>12 months) follow up and complete data on steroid use were available in 15/28, with 12/15 (80%) remaining steroid free at 1 year.Conclusion: Short-term dose tailoring regains disease response in the majority of patients with CD. Of these, most will remain free of corticosteroids at 1 year after de-escalating therapy.
Keywords: Crohn disease; Infliximab; Adalimumab; Anti-TNF-α, Dose escalation
Rights: © 2014 Royal Australasian College of Physicians
DOI: 10.1111/imj.12621
Published version:
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.